Health Care·Life Sciences Tools & Services·$174.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.89 | N/A | +45.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.89 | N/A | +45.86% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their ability to adapt to current market challenges. They emphasized a focus on operational efficiency.
The company is pleased with the strong EPS performance this quarter.
We are navigating through challenging market conditions effectively.
Thermo Fisher Scientific's strong EPS performance indicates robust profitability, which contributed to a 1.9% increase in stock price following the earnings report. The lack of revenue data and forward guidance leaves some uncertainty, but the positive EPS surprise suggests the company is managing well in the current environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KONINKLIJKE PHILIPS ADR
Jul 20, 2020